Gleevec
Executive Summary
Novartis conducted all trials submitted for the approval of imatinib mesylate for the treatment of chronic myeloid leukemia. The National Cancer Institute is conducting further trials of Gleevec in gastrointestinal stromal tumors and in different areas of CML ("The Pink Sheet", May 14, p. 3)